Tsimikas, S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J. Am. Coll. Cardiol. 69, 692–711 (2017).

Article  CAS  PubMed  Google Scholar 

Tsimikas, S. et al. NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J. Am. Coll. Cardiol. 71, 177–192 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

van der Valk, F. M. et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation 134, 611–624 (2016).

Article  PubMed  PubMed Central  Google Scholar 

Kronenberg, F. et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur. Heart J. 22, 3925–3946 (2022).

Article  Google Scholar 

Clarke, R. et al. Oxidized phospholipids on apolipoprotein B-100 versus plasminogen and risk of coronary heart disease in the PROCARDIS study. Atherosclerosis 354, 15–22 (2022).

Article  CAS  PubMed  Google Scholar 

Boffa, M. B. & Koschinsky, M. L. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? J. Lipid Res. 57, 745–757 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Loscalzo, J., Weinfeld, M., Fless, G. M. & Scanu, A. M. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 10, 240–245 (1990).

Article  CAS  PubMed  Google Scholar 

Etingin, O. R., Hajjar, D. P., Hajjar, K. A., Harpel, P. C. & Nachman, R. L. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J. Biol. Chem. 266, 2459–2465 (1991).

Article  CAS  PubMed  Google Scholar 

Palabrica, T. M. et al. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat. Med. 1, 256–259 (1995).

Article  CAS  PubMed  Google Scholar 

Helgadottir, A. et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J. Am. Coll. Cardiol. 60, 722–729 (2012).

Article  CAS  PubMed  Google Scholar 

Kamstrup, P. R., Tybjaerg-Hansen, A. & Nordestgaard, B. G. Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler. Thromb. Vasc. Biol. 32, 1732–1741 (2012).

Article  CAS  PubMed  Google Scholar 

Dentali, F. et al. Lipoprotein(a) as a risk factor for venous thromboembolism: a systematic review and meta-analysis of the literature. Semin. Thromb. Hemost. 43, 614–620 (2017).

Article  CAS  PubMed  Google Scholar 

Boffa, M. B. et al. Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis. J. Lipid Res. 60, 2082–2089 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Belczewski, A. R. et al. Baboon lipoprotein(a) binds very weakly to lysine-agarose and fibrin despite the presence of a strong lysine-binding site in apolipoprotein(a) kringle IV type 10. Biochemistry 44, 555–564 (2005).

Article  CAS  PubMed  Google Scholar 

Tsimikas, S., Moriarty, P. M. & Stroes, E. S. Emerging RNA therapeutics to lower blood levels of Lp(a): JACC focus seminar 2/4. J. Am. Coll. Cardiol. 77, 1576–1589 (2021).

Article  CAS  PubMed  Google Scholar 

Kiefer, T. L. & Becker, R. C. Inhibitors of platelet adhesion. Circulation 120, 2488–2495 (2009).

Article  PubMed  Google Scholar 

Gurbel, P. A., Jeong, Y. H., Navarese, E. P. & Tantry, U. S. Platelet-mediated thrombosis: from bench to bedside. Circ. Res. 118, 1380–1391 (2016).

Article  CAS  PubMed  Google Scholar 

Coughlin, S. R. Protease activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost. 3, 1800–1814 (2005).

Article  CAS  PubMed  Google Scholar 

Zimmerman, G. A., McIntyre, T. M., Prescott, S. M. & Stafforini, D. M. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit. Care Med. 30, S294–S301 (2002).

Article  CAS  PubMed  Google Scholar 

Tsironis, L. D., Mitsios, J. V., Milionis, H. J., Elisaf, M. & Tselepis, A. D. Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase. Cardiovasc. Res. 63, 130–138 (2004).

Article  CAS  PubMed  Google Scholar 

Patrono, C. & Baigent, C. Role of aspirin in primary prevention of cardiovascular disease. Nat. Rev. Cardiol. 16, 675–686 (2019).

Article  PubMed  Google Scholar 

Malle, E., Ibovnik, A., Stienmetz, A., Kostner, G. M. & Sattler, W. Identification of glycoprotein IIb as the lipoprotein(a)-binding protein on platelets. Lipoprotein(a) binding is independent of an arginyl-glycyl-aspartate tripeptide located in apolipoprotein(a). Arterioscler. Thromb. 14, 345–352 (1994).

Article  CAS  PubMed  Google Scholar 

Ezratty, A., Simon, D. I. & Loscalzo, J. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry 32, 4628–4633 (1993).

Article  CAS  PubMed  Google Scholar 

Martinez, C. et al. Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation. Thromb. Haemost. 85, 686–693 (2001).

Article  CAS  PubMed  Google Scholar 

Rand, M. L. et al. Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler. Thromb. Vasc. Biol. 18, 1393–1399 (1998).

Article  CAS  PubMed  Google Scholar 

Podrez, E. A. et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat. Med. 13, 1086–1095 (2007).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dou, H. et al. Oxidized phospholipids promote NETosis and arterial thrombosis in LNK(SH2B3) deficiency. Circulation 144, 1940–1954 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malle, E. et al. Lysine modification of LDL or lipoprotein(a) by 4-hydroxynonenal or malondialdehyde decreases platelet serotonin secretion without affecting platelet aggregability and eicosanoid formation. Arterioscler. Thromb. Vasc. Biol. 15, 377–384 (1995).

Article  CAS  PubMed  Google Scholar 

Boonmark, N. W. & Lawn, R. M. The lysine-binding function of Lp(a). Clin. Genet. 52, 355–360 (1997).

Article  CAS  PubMed  Google Scholar 

Barre, D. E. Arginyl-glycyl-aspartyl (RGD) epitope of human apolipoprotein (a) inhibits platelet aggregation by antagonizing the IIb subunit of the fibrinogen (GPIIb/IIIa) receptor. Thromb. Res. 119, 601–607 (2007).

Article  CAS  PubMed  Google Scholar 

Bergmark, C. et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J. Lipid Res. 49, 2230–2239 (2008).

Article  CAS  PubMed  Google Scholar 

Leibundgut, G. et al. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J. Lipid Res. 54, 2815–2830 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sotiriou, S. N. et al. Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J. 20, 559–561 (2006).

Article  CAS  PubMed  Google Scholar 

Morrow, D. A. et al. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366, 1404–1413 (2012).

Article  CAS  PubMed  Google Scholar 

Liu, H., Fu, D., Luo, Y. & Peng, D. Independent association of Lp(a) with platelet reactivity in subjects without statins or antiplatelet agents. Sci. Rep. 12, 16609 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Byun, Y. S. et al. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J. Am. Coll. Cardiol. 65, 1286–1295 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar